Sudarshan Pharma Industries reported a 56.8% rise in net profit to ₹2,198.16 lakh for the financial year ended March 31, 2026, compared to ₹1,402.16 lakh in the previous year. Revenue from operations increased 32.8% to ₹66,749.85 lakh from ₹50,249.34 lakh in FY25, while total income rose to ₹67,590.29 lakh. The board approved the audited standalone financial results on April 30, 2026, with statutory auditors issuing an unmodified review opinion.

The company voluntarily adopted Indian Accounting Standards (Ind AS) with a transition date of April 1, 2024, effective from April 1, 2025. This shift from Indian GAAP required a reconciliation of net profit, which stood at ₹1,402.17 lakh under Ind AS for FY25 compared to ₹1,587.70 lakh under previous GAAP. The adoption impacted metrics such as the amortisation of right-of-use assets and expected credit losses.

Financial Performance

For the year ended March 31, 2026, the company reported a profit before tax of ₹2,866.82 lakh, up from ₹1,880.61 lakh in the prior year. Total expenses for the period increased to ₹64,723.48 lakh from ₹48,386.88 lakh, primarily driven by higher purchases of stock-in-trade and finance costs. Earnings per share (EPS) from continuing operations improved to ₹0.91 basic and ₹0.90 diluted from ₹0.58 in the previous year.

Corporate Developments

The Board approved raising funds up to ₹1,500 crore via Foreign Currency Convertible Bonds (FCCBs). Following an Extraordinary General Meeting on August 11, 2025, the company received in-principle approval from BSE Limited to issue FCCBs up to USD 35,000,000. The Reserve Bank of India approved a fresh Loan Registration Number for the fund-raising proposal on March 25, 2026, after a previous attempt did not fructify.

In a strategic expansion, the company entered into a definitive agreement on August 4, 2025, to acquire an operational manufacturing facility in Telangana from Srigen Lifesciences Private Limited for ₹25.50 crore. The facility includes land, building, and plant & machinery. Additionally, the company has received ₹4.68 crore, including interest, towards a legal award of approximately ₹9.19 crore from a Dubai court against Regans International DMCC.

Sudarshan Pharma Industries Limited has dispatched the postal ballot notice to shareholders on May 25, 2026, seeking approval for the migration of its equity shares from the SME Platform of BSE Limited to the Main Board of BSE and for listing on the Main Board of National Stock Exchange of India Limited. The notice was published in Mumbai Lakshdeep and Financial Express. The remote e-voting period is scheduled from May 26, 2026, at 9:00 a.m. IST to June 24, 2026, at 5:00 p.m. IST.

Migration and Listing Proposals

The company's 24,06,58,870 equity shares of ₹1 each are currently listed and traded on the SME platform of BSE. Having been listed on March 22, 2023, for over three years with a paid-up capital exceeding ₹10 Crores, the company is eligible to migrate to the Main Board as per SEBI ICDR Regulations. The Board of Directors approved these proposals on May 21, 2026. The resolutions require a special majority, where votes cast by public shareholders in favor must be at least two times the votes cast against them.

Director Appointments

The postal ballot also includes resolutions for the appointment of two directors. Mr. Sanat Bhat (DIN: 08059016) is proposed for appointment as an Independent Director for a term of five years from May 1, 2026, to April 30, 2031. Additionally, Dr. Vinay Pandey (DIN: 10084203) is proposed for appointment as a Non-Executive Non-Independent Director, liable to retire by rotation. Both appointments were recommended by the Nomination & Remuneration Committee.

Voting and Oversight Details

National Securities Depository Limited (NSDL) has been engaged to facilitate the remote e-voting facility. Mr. Vishal N. Manseta, Practicing Company Secretary, has been appointed as the Scrutinizer to ensure the process is conducted fairly. The results of the postal ballot are expected to be announced on June 25, 2026. The notice has been dispatched electronically to members whose email addresses are registered with the company or depositories as of the cut-off date of May 22, 2026.